Statins and the risk of rhabdomyolysis

Journal of Endocrinological Investigation

Volumn 25, Issue 7, 2002, Pages 577-

  Rosenson, R S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE SALT; CERIVASTATIN; CREATINE KINASE; CREATININE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LIPID; MEVINOLIN; NICOTINIC ACID; STATIN DERIVATIVE; UNCLASSIFIED DRUG;

AGE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG COST; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDITORIAL; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIFESTYLE; LIPOPHILICITY; MEDICAL DECISION MAKING; METABOLIC DISORDER; MYOPATHY; NONHUMAN; PATIENT INFORMATION; PRESCRIPTION; RHABDOMYOLYSIS; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 0036062093     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345078     Document Type: Editorial

References (13)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPST/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
5. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial. Cerivastatin Study Group
6. Rosuvastatin for the treatment of patients with hypercholesterolemia
7. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
8. Cerivastatin and reports of fatal rhabdomyolysis
9. Physician's interpretation of "Class effects" a need for thoughtful revisit
10. Prevalence of the metabolic syndrome amng US adults. Findings from the third national health and nutrition examination survey
11. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III)
12. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia
13. Statin-fibrate combinations in patients with combined hyperlipidemia